Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly

Influenza Clinical Trial

Official title:

Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00772889
• Other study ID #: 111738
• Status: Completed
• Phase: Phase 3
• Start date: October 9, 2008
• Est. completion date: December 15, 2009

Study information

• Verified date: April 2017
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this observer-blind clinical trial is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in the elderly. Subjects were previously vaccinated (NCT00529516).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 971
• Est. completion date: December 15, 2009
• Est. primary completion date: December 15, 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

• A male or female subject previously enrolled in study 109821 (NCT 00529516) in the >= 65 years and 18-41 years of age groups and having received the study vaccine.

• Subjects of whom the investigator believes that they can and will comply with the requirements of the protocol. Specific attention should be given to the compliance potential of subjects with suspected or known drug or alcohol abuse.

• Written informed consent obtained from the subject.

• Free of an acute aggravation of the health status as established by medical history and clinical examination before entering into the study

• If the subject is female, she must be of non-childbearing potential or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of the vaccination series.

Exclusion Criteria:

• Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study.

• Planned administration of a vaccine not foreseen by the study protocol up to 30 days after vaccination.

• Planned administration of an influenza vaccine other than the study vaccines during the entire study period.

• Any vaccination against influenza since January 2008 with any seasonal influenza vaccine.

• Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.

• Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.

• History of hypersensitivity to a previous dose of influenza vaccine.

• History of allergy or reactions likely to be exacerbated by any component of the vaccines.

• Acute (active) clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or pre-existing laboratory screening tests.

• Acute disease at the time of enrolment.

• Administration of immunoglobulins and/or any blood products within the three months preceding the administration of the study vaccine or planned administration during the study period.

• Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days prior to vaccination, or planned use during the study period.

• Any medical conditions in which intramuscular injections are contraindicated.

• Pregnant or lactating females.

• Female planning to become pregnant or planning to discontinue contraceptive precautions.

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Biological:
• Influenza vaccine GSK2186877A
One intramuscularly injection at Day 0
• GSK Biologicals' Fluarix™
One intramuscularly injection at Day 0

Locations

Country	Name	City	State
Belgium	GSK Investigational Site	Gent
Germany	GSK Investigational Site	Augsburg	Bayern
Germany	GSK Investigational Site	Berlin
Germany	GSK Investigational Site	Berlin
Germany	GSK Investigational Site	Berlin
Germany	GSK Investigational Site	Berlin
Germany	GSK Investigational Site	Berlin
Germany	GSK Investigational Site	Haag	Bayern
Germany	GSK Investigational Site	Hoehenkirchen-Siegertsbrunn	Bayern
Germany	GSK Investigational Site	Langquaid	Bayern
Germany	GSK Investigational Site	Leipzig	Sachsen
Germany	GSK Investigational Site	Messkirch	Baden-Wuerttemberg
Germany	GSK Investigational Site	Ruedersdorf	Brandenburg
Norway	GSK Investigational Site	Bekkestua
Norway	GSK Investigational Site	Bergen
Norway	GSK Investigational Site	Elverum
Norway	GSK Investigational Site	Fredrikstad
Norway	GSK Investigational Site	Hamar
Norway	GSK Investigational Site	Haugesund
Norway	GSK Investigational Site	Skien
United States	GSK Investigational Site	Carnegie	Pennsylvania
United States	GSK Investigational Site	Chaska	Minnesota
United States	GSK Investigational Site	Clearwater	Florida
United States	GSK Investigational Site	Coral Gables	Florida
United States	GSK Investigational Site	Erie	Pennsylvania
United States	GSK Investigational Site	Milford	Massachusetts
United States	GSK Investigational Site	Pittsburgh	Pennsylvania
United States	GSK Investigational Site	Poughkeepsie	New York
United States	GSK Investigational Site	Somers Point	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

United States,  Belgium,  Germany,  Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)	Grade 3 ecchymosis, redness and swelling were = 100 millimeters (mm) and grade 3 pain was considerable pain at rest that prevented normal everyday activities. Any was >20 mm for ecchymosis, redness and swelling.	Day 0-6
Primary	Duration of Solicited Local AEs	Duration was defined as number of days with any grade of local symptoms.	Day 0-6
Primary	Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs	Any fever was defined as oral temperature =38.0 degree centigrade (°C), grade 3 fever was oral temperature = 39.0°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relationship to the study vaccination, grade 3 was defined as a general symptom that prevented normal activity. Related arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever were defined as general symptoms assessed by the investigator as causally related to the study vaccination.	Day 0-6
Primary	Duration of Solicited General AEs	Duration was defined as number of days with any grade of general symptoms.	Day 0-6
Primary	Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs	Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade. Grade 3 was defined as an unsolicited symptom that prevented normal activity. Related was an event assessed by the investigator as causally related to the study vaccination.	Day 0-20
Primary	Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit (MAEs) During Day 0 to Day 20	For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as a symptom that prevented normal activity and related was a general symptom assessed by the investigator as causally related to the study vaccination.	Day 0-20
Primary	Number of Subjects Reporting AEs of Specific Interest (AESI) Including Autoimmune Diseases From Day 0 to Day 20	AESI for safety monitoring are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Any was defined as occurrence of any symptom regardless of intensity grade.	Day 0-20
Primary	Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) From Day 0 to Day 20	SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was an event assessed by the investigator as causally related to the study vaccination.	Day 0-20
Secondary	Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit (MAEs) Between Day 21 and Day 179	For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as a symptom that prevented normal activity and related was a general symptom assessed by the investigator as causally related to the study vaccination.	Day 21-179
Secondary	Number of Subjects Reporting AEs of Specific Interest (AESI) Including Autoimmune Diseases Between Day 21 and Day 364	AESI for safety monitoring are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as a symptom that prevented normal activity and related was a general symptom assessed by the investigator as causally related to the study vaccination.	Day 21-364.
Secondary	Haemagglutination Inhibition (HI) Antibody Titers	Antibody titers were expressed as Geometric mean titres (GMTs) per separate vaccine strain. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.	Day 0-21
Secondary	The Number of Subjects Seropositive to HI Antibodies	A seropositive subject was defined as a subject with antibody titer greater than or equal to the cut-off value i.e = 1:10. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.	Day 0-21
Secondary	The Number of Subjects Seroprotected by HI Antibodies	A seroprotected subject was defined as a subject with a serum HI titer = 1:40 that usually is accepted as indicating protection. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.	Day 0-21
Secondary	The Number of Subjects Seroconverted to HI Antibodies	A seroconverted subject was defined as a subject who had either a pre-vaccination titer < 1:10 and a post-vaccination titer = 1:40 or a pre-vaccination titer = 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.	At Day 21
Secondary	HI Antibody Seroconversion Factors (SCF)	SCF was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.	At Day 21
Secondary	Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) From Day 21 to Day 364	SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was an event assessed by the investigator as causally related to the study vaccination.	Day 21-364

External Links

•   Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.